Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C20H18FNO4
CAS Number:
Molecular Weight:
355.36
MDL number:
NACRES:
NA.21
color
white to yellow
SMILES string
Fc1c(ccc(c1)c3cc(ccc3)OC)NC(=O)C2=C(CCC2)C(=O)O
InChI
1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
InChI key
XPRDUGXOWVXZLL-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor in cultures and in vivo.
Vidofludimus (4SC-101) is an orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor (human DHODH IC50 = 134 nM; IC50 = 13 µM against PHA-stimulated lymphocytes proliferation) that inhibits PHA-induced IL-17 secretion from human PBMCs (IC50 = 6 µM) and exhibits therapeutic efficacy in murine models of colitis (50-100 mg/kg/d via intragastric administration; chronic dextran sodium sulfate-induced and acute TNBS-induced colitis) and a rat model of renal transplantation in vivo (20 mg/kg/d p.o.).
Vidofludimus (4SC-101) is an orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor (human DHODH IC50 = 134 nM; IC50 = 13 µM against PHA-stimulated lymphocytes proliferation) that inhibits PHA-induced IL-17 secretion from human PBMCs (IC50 = 6 µM) and exhibits therapeutic efficacy in murine models of colitis (50-100 mg/kg/d via intragastric administration; chronic dextran sodium sulfate-induced and acute TNBS-induced colitis) and a rat model of renal transplantation in vivo (20 mg/kg/d p.o.).
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Onkar P Kulkarni et al.
The American journal of pathology, 176(6), 2840-2847 (2010-04-24)
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better toxicity profiles are needed. Dihydroorotate dehydrogenase (DHODH) inhibition with leflunomide has proven to be effective in autoimmune diseases including SLE, but leflunomide can cause a
Leo R Fitzpatrick et al.
Inflammatory bowel diseases, 16(10), 1763-1777 (2010-03-24)
Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for the treatment of autoimmune diseases. 4SC-101 is a novel immunosuppressive drug that inhibits DHODH. A goal of our study was to examine the
Krisztina Rusai et al.
Transplantation, 93(11), 1101-1107 (2012-05-23)
4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with beneficial effects in experimental lupus and inflammatory bowel disease. Its immunomodulatory effect on acute kidney rejection is not known; therefore, in this study, the impact
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service